AMBENIUM™ PARENTERAL solution for i.m. injection 373.4mg/2ml+3.75mg/2ml (2ml), 3pcs

AMBENIUM™ 373.4mg+3.75mg Solution 2ml Buy Online

Ambenium Parenteral: A Powerful Analgesic and Anti-inflammatory Solution

Experiencing debilitating pain and inflammation? Ambenium Parenteral offers a potent solution for managing acute symptoms associated with various conditions. This injectable formulation provides rapid relief, targeting the source of discomfort and promoting healing. Its unique composition combines the power of phenylbutazone with the localized anesthetic effect of lidocaine, offering a comprehensive approach to pain management.

Understanding Ambenium Parenteral

Ambenium Parenteral is a sterile, injectable solution designed for the symptomatic treatment of pain and inflammation. Its unique formulation combines two active ingredients: phenylbutazone, a nonsteroidal anti-inflammatory drug (NSAID) with potent analgesic and anti-inflammatory properties, and lidocaine, a local anesthetic that helps minimize injection site discomfort. This combination provides targeted relief, addressing both the underlying inflammation and the immediate pain associated with administration.

The preparation is specifically formulated as a solution for intramuscular (i.m.) injection, ensuring rapid absorption and distribution throughout the body. This allows for quicker onset of action compared to oral formulations, making it particularly suitable for the management of acute pain episodes. The precise balance of phenylbutazone and lidocaine in Ambenium Parenteral is carefully designed to optimize therapeutic efficacy while minimizing potential side effects. This makes it a valuable tool in the arsenal of pain management strategies.

Phenylbutazone works by inhibiting cyclooxygenases (COX-1 and COX-2), enzymes involved in the production of prostaglandins, which are mediators of inflammation and pain. By reducing prostaglandin synthesis, phenylbutazone effectively decreases inflammation, swelling, and pain. Lidocaine, on the other hand, acts by blocking nerve impulses, thereby providing local anesthesia at the injection site. The combined action of these two components results in a synergistic effect, providing both rapid pain relief and a reduction in the underlying inflammatory process. This targeted approach is crucial for effective management of acute pain situations.

Mechanism of Action

Ambenium Parenteral’s efficacy stems from the synergistic action of its two key components: phenylbutazone and lidocaine. Phenylbutazone, a non-steroidal anti-inflammatory drug (NSAID), exerts its effects by non-selectively inhibiting cyclooxygenases (COX-1 and COX-2). These enzymes are crucial in the production of prostaglandins, inflammatory mediators responsible for pain and swelling. By reducing prostaglandin synthesis, phenylbutazone effectively diminishes inflammation and pain.

The addition of lidocaine, a local anesthetic, provides immediate pain relief at the injection site. Lidocaine achieves this by blocking sodium channels in nerve cells, preventing the transmission of pain signals. This dual mechanism of action ensures both rapid pain relief from the injection itself and a longer-term reduction in inflammation and associated pain. The combined effect of these two active components provides a comprehensive approach to managing acute pain and inflammation.

Importantly, the rapid absorption of phenylbutazone following intramuscular injection contributes to its swift onset of action. This rapid absorption, coupled with lidocaine’s immediate local anesthetic effect, makes Ambenium Parenteral a particularly effective treatment option for acute pain flare-ups. The precise pharmacokinetic profile of each component is crucial to the overall therapeutic effect, ensuring a balance between rapid pain relief and sustained anti-inflammatory action, minimizing the duration of discomfort and promoting healing.

Pharmacokinetics

Following intramuscular administration, phenylbutazone is rapidly absorbed, reaching peak plasma concentrations within approximately two hours. Subsequently, therapeutic concentrations are maintained for several hours, typically representing 80-90% of the maximum concentration. This rapid absorption and sustained presence in the bloodstream contribute to Ambenium Parenteral’s rapid onset and prolonged analgesic and anti-inflammatory effects. Metabolism primarily occurs in the liver through oxidation and glucuronidation, resulting in the formation of pharmacologically active metabolites, including oxyphenbutazone.

Elimination of both the parent drug and its metabolites is biphasic, involving both renal excretion (approximately 70%) and biliary excretion (approximately 30%). The elimination half-life (t_1/2) of phenylbutazone is notably long, ranging from 50 to 100 hours, potentially extending significantly in patients with impaired hepatic or renal function. This prolonged half-life necessitates careful consideration of dosage and potential drug interactions, particularly in individuals with compromised organ function. High plasma protein binding (approximately 99%) further influences the pharmacokinetic profile and necessitates awareness of potential displacement interactions.

Lidocaine’s pharmacokinetics are influenced by the dose administered and its site of injection. Absorption is relatively rapid following intramuscular injection, with a linear relationship between the dose and peak plasma concentrations. Plasma protein binding, primarily to α1-acid glycoprotein and albumin, is significant (approximately 66%). Lidocaine crosses both the blood-brain barrier and the placental barrier, highlighting the need for caution in specific patient populations. Hepatic metabolism is the primary route of elimination, with the majority of the dose undergoing N-dealkylation to form metabolites. The terminal half-life of lidocaine is relatively short, typically 1-2 hours following intravenous bolus administration.

Potential Benefits

Ambenium Parenteral offers several key advantages in managing acute pain and inflammation. Its rapid onset of action, thanks to the combined effects of phenylbutazone and lidocaine, provides swift relief from debilitating symptoms. This rapid relief is particularly beneficial in situations requiring immediate pain control. The intramuscular route of administration ensures efficient drug absorption and distribution, leading to quicker symptom improvement compared to oral formulations. This rapid response is critical in managing acute pain episodes, allowing patients to return to a more comfortable state sooner.

The formulation’s combined mechanism of action targets both the underlying inflammatory process and the immediate pain sensation. Phenylbutazone’s anti-inflammatory properties address the root cause of the pain, while lidocaine’s local anesthetic effect minimizes discomfort during and immediately after injection. This dual action is significant in minimizing overall pain and discomfort, offering a more comprehensive approach than using a single analgesic or anti-inflammatory agent alone. The combined action is crucial in reducing the overall burden of the inflammatory condition and enhancing recovery.

Ambenium Parenteral may be particularly beneficial for individuals experiencing acute exacerbations of chronic inflammatory conditions such as ankylosing spondylitis, rheumatoid arthritis, or gout. By rapidly alleviating pain and inflammation, it can improve mobility, reduce discomfort, and enhance the patient’s quality of life during these flare-ups. The ability to provide rapid and targeted relief makes it a valuable tool for managing acute pain episodes associated with various conditions while promoting improved functional capacity during periods of exacerbation.

Pros

• Rapid pain relief: Ambenium Parenteral’s unique formulation provides swift and effective pain relief due to the combined action of phenylbutazone and lidocaine, offering immediate comfort.
• Targeted dual action: It tackles both the inflammatory process and the pain sensation simultaneously, addressing the root cause and the symptom effectively.
• Intramuscular administration: This route ensures efficient absorption and distribution, leading to a faster onset of action compared to oral medication, crucial for acute situations.
• Potent anti-inflammatory effects: Phenylbutazone’s potent anti-inflammatory properties significantly reduce swelling and associated discomfort, promoting healing.
• Reduced injection site pain: Lidocaine’s local anesthetic effect minimizes discomfort during and immediately after the injection, enhancing patient compliance.
• Suitable for acute exacerbations: It is particularly useful for managing flare-ups of chronic inflammatory conditions, providing rapid symptom control and improved quality of life.

Potential Risks

While Ambenium Parenteral offers significant benefits, it’s crucial to acknowledge potential risks associated with its use. Like other NSAIDs, phenylbutazone can cause gastrointestinal side effects, ranging from mild nausea and diarrhea to more severe complications such as ulcers, bleeding, and perforation. These risks are heightened in patients with pre-existing gastrointestinal conditions or those taking other medications that can increase the risk of bleeding. Regular monitoring and careful patient selection are essential to mitigate these risks. Early detection and management of any gastrointestinal symptoms is crucial.

Furthermore, Ambenium Parenteral carries a risk of allergic reactions, ranging from mild skin rashes to potentially life-threatening anaphylaxis. Patients with a history of allergies to NSAIDs or other drugs should exercise extreme caution and inform their healthcare provider. Immediate medical attention should be sought if any signs of an allergic reaction, such as swelling, difficulty breathing, or a rapid heartbeat, occur. Appropriate emergency preparedness is essential given this risk profile.

Other potential adverse effects include effects on the hematologic system (anemia, leukopenia, thrombocytopenia), liver function abnormalities, and renal impairment. These adverse events underscore the importance of careful patient selection, regular monitoring of blood counts and liver and kidney function, and prompt discontinuation of the medication if any concerning changes are observed. Close clinical supervision is therefore necessary to minimize the potential for serious adverse effects. Early identification and management of such problems are critical.

Cons

• Gastrointestinal risks: Ambenium Parenteral, like other NSAIDs, can cause gastrointestinal side effects, including nausea, diarrhea, ulcers, and bleeding. These risks are heightened in patients with pre-existing conditions or those on concomitant medications that increase bleeding risk.
• Allergic reactions: Allergic reactions, ranging from mild rashes to severe anaphylaxis, are possible. Patients with a history of NSAID allergies should be cautious and closely monitored.
• Hematologic effects: The medication can affect blood cell counts, potentially leading to anemia, leukopenia, or thrombocytopenia. Regular blood monitoring is advisable during treatment.
• Hepatotoxicity and nephrotoxicity: Liver and kidney function abnormalities are potential adverse effects, necessitating careful monitoring, especially in patients with pre-existing conditions.
• Long elimination half-life: The extended half-life of phenylbutazone increases the risk of drug accumulation and interactions with other medications, requiring careful dosage adjustments.
• Contraindications: Ambenium Parenteral is contraindicated in several patient groups, such as those with severe hepatic or renal impairment, active gastrointestinal ulcers, or a history of hypersensitivity to NSAIDs. Careful evaluation of patient history is therefore critical before administration.

Dosage and Administration

Ambenium Parenteral is administered via intramuscular injection. The typical dose for acute pain management or exacerbation of chronic conditions is a single injection of 373.4 mg (2 mL). This dose should be administered slowly and deeply into the muscle to ensure proper absorption and minimize discomfort. The injection site should be rotated with subsequent administrations to prevent local irritation. Always follow the instructions provided by your healthcare professional.

It is crucial to emphasize that the dosage and frequency of administration should be determined and closely monitored by a healthcare professional. Individual patient factors, such as age, weight, and renal or hepatic function, may influence the appropriate dose. Self-administration is strongly discouraged. The physician will make adjustments based on individual response and any potential side effects experienced. Improper administration can lead to complications, such as local tissue damage. Patient education on appropriate administration techniques is crucial.

Patients should be closely monitored for at least one hour following the injection to observe for any immediate adverse reactions. The healthcare provider should be immediately informed of any unusual symptoms or signs of an allergic reaction. Prompt medical attention is crucial in cases of severe adverse events, such as anaphylaxis. Close monitoring during and after the injection helps ensure patient safety and effective treatment.

Contraindications and Precautions

Ambenium Parenteral is contraindicated in several situations. It should not be used in patients with known hypersensitivity to phenylbutazone, lidocaine, or any of the excipients. Individuals with active peptic ulcers, gastrointestinal bleeding, or severe hepatic or renal impairment should also avoid this medication due to the increased risk of serious adverse events. Pregnancy and breastfeeding are additional contraindications, due to potential harm to the developing fetus or infant. Children under the age of 18 should also not receive this medication.

Several precautions should be observed when administering Ambenium Parenteral. Patients with a history of heart conditions, hypertension, or fluid retention should be carefully monitored, as phenylbutazone can exacerbate these conditions. Individuals with a history of asthma or allergic rhinitis may be at increased risk of severe allergic reactions. Concomitant use with other NSAIDs, anticoagulants, or drugs metabolized by the liver should be approached cautiously and often requires careful dose adjustments, to avoid dangerous interactions. Close monitoring is crucial in these scenarios.

Regular monitoring of liver and kidney function, as well as blood counts, is recommended, particularly during prolonged treatment. Patients should be instructed to report any unusual symptoms, such as gastrointestinal distress, skin rashes, or changes in urine output. The healthcare provider should be informed of any other medications the patient is taking to assess potential interactions. Careful patient selection, close monitoring, and adherence to established guidelines are crucial to minimizing risks and ensuring the safe and effective use of Ambenium Parenteral.